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Abstract The objective of this paper was to address the
importance of dealing systematically and comprehensively
with uncertainty in a budget impact analysis (BIA) in more
detail. The handling of uncertainty in health economics
was used as a point of reference for addressing the
uncertainty in a BIA. This overview shows that standard
methods of sensitivity analysis, which are used for standard
data set in a health economic model (clinical probabilities,
treatment patterns, resource utilisation and prices/tariffs),
cannot always be used for the input data for the BIA model
beyond the health economic data set for various reasons.
Whereas in a health economic model, only limited data
may come from a Delphi panel, a BIA model often relies
on a majority of data taken from a Delphi panel. In addi-
tion, the dataset in a BIA model also includes forecasts
(e.g. annual growth, uptakes curves, substitution effects,
changes in prescription restrictions and guidelines, future
distribution of the available treatment modalities, off-label
use). As a consequence, the use of standard sensitivity
analyses for BIA data set might be limited because of the
lack of appropriate distributions as data sources are limited,
or because of the need for forecasting. Therefore, scenario
analyses might be more appropriate to capture the uncer-
tainty in the BIA data set in the overall BIA model.
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Introduction
Health technology assessment (HTA) is ‘‘a multidisci-
plinary ﬁeld of policy analysis, studying the medical,
economic, social and ethical implications of development,
diffusion and use of health technologies’’ [1]. Historically,
HTA agencies have focussed on producing high quality
assessment reports to inform decision-makers. Nowadays
such organisations are increasingly undertaking or com-
missioning HTAs to inform a particular resource allocation
decision, i.e. appraisals such as: listing a drug on a national
or local formulary, deﬁning coverage and insurance plans,
and issuing mandatory guidance on the use of health care
technologies [2]. For many health care systems, three goals
can be identiﬁed: cost containment, cost-effective imple-
mentation of technologies, and a sustainable health care
system requiring instruments encouraging innovations.
These three goals are often in conﬂict with each other.
Therefore, a successful HTA approach for health care
technologies constitutes a balance between three goals.
Escalating costs have become a major concern for
healthcare professionals, decision-makers and the public,
prompting the implementation of new cost containment
measures over the last decade, especially for new phar-
maceuticals. Reimbursement of new pharmaceuticals up to
now was based simply on registration data (efﬁcacy, safety
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distinguish various additional data requirements, especially
relating to the use of innovations in real daily practice. The
most important new data requirements are effectiveness,
cost-effectiveness and budgetary impact. Other consider-
ations might also be taken into account depending on the
speciﬁc indication, e.g. equity in the case of life-style drugs
or orphan drugs.
The focus of this paper is on offering some guidance
for the execution of a budget impact analysis (BIA).
Budget impact data from a ﬁnancial analysis are able to
present the impact of an innovation on a national annual
drug budget as well as on overall health care budgets. The
purpose of a BIA is to estimate the affordability of a new
health care intervention for speciﬁc health care decision-
makers. A deeper insight into budgetary consequences is
necessary in making choices within the context of
unavoidable budgetary restrictions. BIA might become an
essential part of comprehensive economic assessments of
health care programs, along with cost-effectiveness anal-
yses (CEA), before national or local formulary approval
or reimbursement.
The main difference between CEA and BIA is in their
respective goals. CEA looks at a representative individual
or cohort and estimates costs and beneﬁts of the new
intervention over a time horizon that captures all relevant
costs and beneﬁts. CEA thus represents the traditional
approach to health economic evaluation, combining clini-
cal and economic outcomes. In contrast, BIA looks at the
current and future population of interest to the decision
maker and estimates the impact of the new intervention on
short- or longer-term annual healthcare budgets.
There are also other differences, aside from the obvious,
between a health economic and a ﬁnancial analysis:
• The perspective in a health economic study in most
countries is a societal one, including non-medical costs
and indirect costs, and costing ought to be based on
opportunity costs. A ﬁnancial analysis is performed
from the perspective of the payer, includes mainly
medical costs, and costing is based on actual prices and
tariffs.
• The time horizon in a health economic study depends
on the disease and may vary from only an episode (e.g.
treatment of infections) to a life-time in chronic
diseases (e.g. multiple sclerosis). The time horizon
for a ﬁnancial analysis is based on the perspective
(or needs) of the payer and corresponds to budgeting
periods varying from 1 year up to 5 years.
• The target audiences for health economic studies are
usually central reimbursement authorities, which have
an interest in aggregated outcomes. The target audi-
ences of ﬁnancial analyses are also central authorities,
but may also include regional decision-makers (insur-
ers, hospitals), where organisational structure often
results in a silo-mentality leading to a higher interest in
disaggregated outcomes. For example, a hospital phar-
macist might be interested only in the impact of a new
pharmaceutical on his drug budget, regardless of other
cost savings for the hospital, e.g. a reduction in length
of stay.
The development of prescription restrictions is another
policy tool used to control the costs of pharmaceuticals that
is closely linked to BIA. While traditionally reimbursement
decisions were based on the registered indication, author-
ities have recently started issuing restrictions on claims
made for a drug. Through the creation of prescription
guidelines for certain conditions, healthcare authorities can
exercise control over physicians’ prescribing. These rec-
ommendations are seen as an extension of non-reim-
bursement lists. The primary goal of a prescription
restriction is to reduce and control the budget impact of the
reimbursement of a new pharmaceutical. Therefore, pre-
scription restriction and BIA are closely related: a pre-
scription restriction is often developed based on the
outcome of a BIA for the registered indication, if the
assumed budget impact is too high.
The primary purpose of a BIA should be to provide
information on the organisational and economic conse-
quences of the implementation of a new technology in
order to create space and budgets for the introduction of
new cost-effective technologies. Similarly, BIA should also
be used to identify corresponding decreased budgets due to
withdrawal of non cost-effective technologies. However,
our experience is that the purpose of a BIA is often mis-
understood because it has been used mainly as a tool for
slowing down the speed of the uptake of new technologies.
Examples of the use of BIA as a tool for analysing with-
drawal of non cost-effective treatments are rare.
If BIA is used for reimbursement issues by authorities or
third-party payers, it is vital that such analyses are per-
formed according to generally accepted and standardised
methods. This increases the transparency of a ﬁnancial
analysis, allowing for more rational interpretation of the
BIA results and a better comparison of different analyses
for new pharmaceuticals. This is especially important when
budget constraints allow the reimbursement of only a
limited number of new pharmaceuticals. Guidelines for
cost-effectiveness studies were developed initially in
Australia [3] and Canada [4], but are currently available for
most Western countries, e.g. Germany [5]. However,
national authorities in the past rarely published any BIA
guidelines. To ﬁll this gap, an International Society For
Pharmacoeconomics and Outcomes Research (ISPOR)
Task Force published the ﬁrst international guideline for
232 M. J. C. Nuijten et al.
123the execution of a BIA, also describing a general approach
for the handling of uncertainty [6].
The objective of this paper is to address in more detail
the importance of dealing systematically and comprehen-
sively with the uncertainty in a BIA. The handling of
uncertainty in health economics is used as a point of ref-
erence for addressing the uncertainty in a BIA, as a sub-
stantial number of methodologies have already been
developed for CEA that may be applicable for BIA. The
ﬁrst part of this paper describes the modelling design of a
BIA and the required data input for the BIA model and its
data sources. The second part describes the handling of
uncertainty in the BIA model.
Design of a BIA
Model design
The design of a new innovative drug will usually be a
modelling study based on decision analytic techniques, as a
population-based cohort study is not feasible. Therefore,
the handling of uncertainty in cost-effectiveness modelling
studies may be applicable to a BIA model. A cost-effec-
tiveness model should, as much as possible, reﬂect the real
life situation of the disease, incorporating current treatment
patterns with input values (probabilities and items of
healthcare utilisation) deviating as little as possible from
population values [7]. This requirement for a cost-effec-
tiveness model applies also to BIA, as the aim of BIA is to
show the impact of a new drug on the annual national drug
budget and/or the overall health care budget in daily
practise after launch. Models may take the form of simple
decision-analytic trees or may be very complex Markov
models of underlying disease processes and treatments.
Building on those ﬁndings, the BIA model might be an
extension of a cost-effectiveness model [8].
To illustrate this approach, a model was constructed for
a new hypothetical drug in Parkinson’s disease, which
allowed us to determine the budgetary impact and the cost-
effectiveness of a new drug from the society perspective in
The Netherlands. This study presents a model for an
appropriate assessment of the budgetary impact of a new
drug, which can be used simultaneously for traditional
CEA. [8] The use of a Markov model allowed both a
ﬁnancial analysis and a CEA to be performed. The
advantage of combining BIA and CEA is that the analyses
are based on the same underlying assumptions and data,
which will increase the consistency between the outcomes
of both analyses.
However, the BIA model may also be developed
independently from the cost-effectiveness model, which
could result in different structures for the two models.
For example, a cost-effectiveness model often requires a
complex Markov structure, whereas a BIA model may often
be based on a more simple structure.
A BIA model depends on the pathology, including
underlying pathophysiological mechanisms, prognosis,
disease progression, and existing treatment options, all of
which are relevant to the design of the BIA study.
Prognosis
Many diseases will not lead to a complete recovery. There
might be: (1) an increased risk of relapse (e.g. depression),
(2) incomplete recovery (e.g. stroke), or (3) other mor-
bidities (e.g. myocardial infarction due to angina pectoris).
In addition, disease progression may be characterised by
(1) episodes with intermittent symptom-free periods;
(2) exacerbations, from which there may be only partial
recovery, leaving the patient in a worse health state after
each episode (e.g. multiple sclerosis); or (3) a more con-
tinuous chronic character (e.g. Parkinson’s disease).
A patient may also have a higher risk of co-morbidities
than the general population (e.g. infections) regardless of
his/her disease progression. This information is needed to
decide on the type of BIA model (prevalence-based BIA
model, incidence-based BIA model or a BIA model based
on both prevalence and incidence) and its characteristics
(need of health states, pathways, follow-up period) and
effectiveness measure(s). Prevalence-based and incidence-
based models are often developed independently from the
cost-effectiveness model, because those models usually do
not require the complexity of a cost-effectiveness model.
However, a BIA model that includes prevalence and inci-
dence often does require the complexity of a cost-effec-
tiveness model, and therefore can be based on an extension
of the underlying cost-effectiveness model.
Choice of comparator
The choice of the comparator is based primarily on coun-
try-speciﬁc treatment patterns and clinical guidelines.
Relevant comparators may include other drugs, other
medical care such as surgery or watchful waiting, or no
treatment. One difference compared to a cost-effectiveness
study is that a BIA evaluation does not consider the com-
parator as a single treatment modality, and consists of a
comparison with separate homogenous comparators. The
comparator in a BIA study consists of a mix of available
treatment modalities in a health care setting from the per-
spective of a speciﬁc target audience. The comparator mix
might also be used to decide on model characteristics.
Finally, information on the type of physician (GP or spe-
cialist) and setting (in-patient or out-patient) associated
with each treatment modality helps to deﬁne the
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outcomes. For example, the comparator mix from a hos-
pital perspective may be different from the insurer’ per-
spective; the comparator mix may also differ between
regions.
Cost effectiveness model
Three different types of data can be distinguished in a cost-
effectiveness model:
1. Clinical probabilities. These mostly cannot be inﬂu-
enced by a physician and are derived from clinical
measures. Examples of clinical probabilities are
response to a treatment, relapse after a previous
response, and mortality.
2. Treatment patterns. In addition to standard therapy
being the ﬁrst choice of therapy for the total cohort
entering the model, the following decisions on the
choice of therapy may occur in the model: (i) therapy
after a response (termination of treatment or continu-
ation of treatment) (ii) therapy after a treatment failure
in response to the initial treatment; and (iii) therapy
after a treatment failure, for example, a change to
second-choice therapy.
3. Costing information. Costing involves estimating the
units of healthcare utilisation used and their prices/
tariffs (product of unit and price).
The data for a cost-effectiveness model may come from
a variety of sources and are subject to varying degrees of
uncertainty. Data sources for the variables being used in a
cost-effectiveness model may be clinical trials, literature
(e.g. meta-analysis), databases, medical records, Delphi
panels and/or ofﬁcial tariff lists. These data sources will
yield, for each variable, a ﬁxed input value and a range.
The cost-effectiveness model calculates costs at the
patient level, whereas the BIA calculates costs at a popu-
lation level. Therefore, a BIA model can be considered an
extension of the cost-effectiveness model. The translation
from cost per patient to budget impact at the population
level requires an additional step. The cost-effectiveness
model may be used to calculate the average cost per patient
over each subsequent year after initiation with the new
treatment. The next step is to calculate the budget impact
by multiplying the average cost per patient by the number
of patients by the incorporation of epidemiology data and
other speciﬁc data (e.g. diffusion curves) for a ﬁnancial
analysis (Table 1).
The potential number of candidates of the target popu-
lation for a new pharmaceutical depends on epidemiology
(prevalence and incidence of the pathology), prescription
restrictions, growth of the target population, off-label use,
and the existing treatment mix and diffusion curves.
Handling of uncertainty in BIA
Measurement of uncertainty
Sensitivity analyses aim at providing information on the
degree of uncertainty in economic evaluations, and are
currently the most widely applied method of dealing with
uncertainty in economic evaluations [9]. The methods
used, the choice of parameters and the range of these
parameters must be stated and substantiated.
The conventional approach is a ‘one-way’ sensitivity
analysis, which varies one of the input variables from its
baselinevalueswhileobservingthe effect on the outcome of
the model. In a multivariate sensitivity analysis more than
one input variable is varied. A probabilistic sensitivity
analysis (PSA) permits the analyst to assign a range and
distribution to input variables [10]. The results of a PSA are
presented in a cost-effectiveness acceptability curve, which
displaystheprobabilitythatanewtreatmentisthemostcost-
effective treatment considered in the analysis at a range of
different threshold incremental cost-effectiveness ratio
(ICER) values representing what society might be willing to
pay to gain one, e.g., quality-adjusted life year (QALY).
The approach of handling uncertainty in cost-effective-
ness models is also applicable to components of the BIA
model that relate to the above-mentioned types of data
(clinical probabilities, treatment patterns, resource utilisa-
tion and prices/tariffs). Although the structure of the BIA
model may differ from the cost-effectiveness model, the
required data on clinical probabilities, treatment patterns,
Table 1 Input parameters in a budget impact analysis (BIA) for cost
per patient, number of patients, and time horizon
BIA Input parameters
Cost per patient Probabilities
Treatment patterns
Costing information: resource utilisation
and prices and tariffs
Number of
patients
Prevalence
Incidence
Proportion of identiﬁed patients
Proportion of eligible patients
Proportion of patients in clinical trials
Annual growth rate for utilisation
of the technology
Existing mix of available treatment modalities
Information on dosing
Treatment sequencing
Diffusion (uptake)
Substitution effects
Off-label use
Time horizon As demanded by the research question at hand
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123resource utilisation and prices/tariffs might be derived from
the cost-effectiveness model.
In the remainder of this manuscript, we will consider the
use of the above-mentioned sensitivity analyses for dealing
with uncertainty in BIA.
Uncertainty in input data for the BIA model
corresponding with the health economic data set
The handling of uncertainty of the input data of the BIA
model, which corresponds with the standard data set for a
cost-effectiveness model (clinical probabilities, treatment
patterns, resource utilisation and prices/tariffs), can be
based on the standard methods of sensitivity analysis that
are used for CEA.
The use of prescription restriction requires cautious
handling of the clinical probabilities. The primary objec-
tive of a phase III clinical trial is to obtain registration by
the ofﬁcial registration authorities (e.g. EMEA, FDA) for a
new drug. Clinical trials for new drugs are usually designed
only with sufﬁcient sample size and power to demonstrate
a clinically meaningful and statistically signiﬁcant differ-
ence (today mostly superiority) for the primary efﬁcacy
outcome in the overall study population. Therefore, a
prescription restriction, which reduces the registration
indication to a smaller subpopulation for reimbursement
purpose, suffers from various methodological weaknesses.
The use of clinical data from subgroup analysis in a BIA
analysis often suffers not only from statistical constraints,
but also from that major methodological weakness that the
trial was designed only for the overall trial population (e.g.
the hypothesis, objective and selection of the primary
clinical outcome). As a consequence, a standard sensitivity
analysis based on the distribution of the clinical probabil-
ities does not capture the total uncertainty associated with
the clinical probabilities. Therefore, additional scenario
analyses must be performed, for example by the extension
of the range or the conﬁdence interval of the clinical input
variables, or the use of clinical probabilities from the
overall study population in the clinical trials.
Other scenarios may also have to be considered, but the
selection of these additional scenario analyses remains
subjective,incontrasttostandardsensitivityanalyses,which
are based on statistical distributions. Therefore, a justiﬁca-
tionoftherationaleofeachscenarioanalysisisimportantfor
interpretationoftheresultsofthebasecaseanalysisofaBIA
and the associated uncertainty in BIA outcomes.
Uncertainty in input data for the BIA model beyond the
health economic dataset
Other input data in the BIA model (BIA data) differ from
the standard health economic dataset. In cases where there
is no valid data from national data sources, the use of a
Delphi panel is the only option for either validation of
international data or adaptation of international data to the
study country of the BIA. In addition, this approach allows
estimates to be elicited when there are no data available or
when the required input information relates to forecasts.
For BIA analyses in The Netherlands the use of data
from Delphi panels in a BIA has been accepted in previous
submissions. Examples of handling missing data by means
of a Delphi panel, as detailed below, were applied in these
BIA analyses. The handling of the following data subsets is
ordered in a step-by-step way to correspond with the topic
sets in the ﬁrst section of this paper describing epidemi-
ologic data needs. In this way, we hope to give the reader a
structured look at the practical issues surrounding incor-
poration of uncertainty in a BIA.
Prevalence and incidence
Prevalence can be the main driver in BIA for chronic
diseases, where the annual inﬂow (incidence) equals the
annual outﬂow of patients (e.g. improvement, progression
or mortality) within the registered indication. Incidence can
be the main driver for episodic diseases with full recovery
or death (e.g. infectious diseases), or diseases where the
initiation of treatment starts at diagnosis and selection of
treatment is based on staging (e.g. adjuvant or advanced
treatment in oncology). Prevalence and incidence data
should be derived from the published literature—ideally
country-speciﬁc literature, e.g. a previous BIA for medi-
cations with similar indication. That data should allow for
the construction of statistical distributions for the standard
sensitivity analysis. If no country-speciﬁc epidemiology
data is available, additional scenario analyses may be
performed in order to capture this additional uncertainty.
International epidemiology data may also be validated by a
Delphi panel of national clinical and epidemiology experts
in order to generate a national estimate with a distribution.
Proportion of patients
Proportion of patients actually identiﬁed by a general
practitioner (GP) or a specialist and really being trea-
ted As an example, the total number of registered rheu-
matoid arthritis (RA) patients was 148,000 in The
Netherlands at the time-of-launch (1999) of currently
available biological agents. However, the total number of
registered adult patients being treated by rheumatologists
ranged between 30,000 and 60,000 patients [11]. As bio-
logicals can be prescribed only by rheumatologists in The
Netherlands, the subpopulation of RA patients being trea-
ted by a rheumatologist yields the potential number of
candidates for treatment. The remaining RA patients are
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logicals, because GPs are not allowed to prescribe these
drugs. On the other hand, there may be a pool of eligible
patients with previous failure on current standard treat-
ment, who may have been lost to follow-up and may return
to their specialist when these patients or their GPs become
aware of biologicals as a new treatment option. This pool
of patients should be considered as a separate cohort of
patients in the BIA because of different patient character-
istics and because this pool has only a temporary budget
impact, as patients with treatment failures before the
introduction of new drugs will disappear over time.
The proportion of patients who actually have been
registered by the GP or specialist and are being treated
might be derived from national databases or published
literature, e.g. a previous BIA for medications with similar
indication, which allows the construction of statistical
distributions for the standard sensitivity analysis. However,
this data often is not available. A national Delphi panel
may be used to elicit an estimate with a distribution. For
example, in a BIA for biologicals in psoriasis, it was not
possible to derive the number of psoriasis patients treated
by a dermatologist from the total number of psoriasis
patients in The Netherlands. Therefore, a Delphi panel
estimated the number of psoriasis patients treated by der-
matologists, which was based on the number of dermatol-
ogists and the number of psoriasis patients treated per
dermatologist. There are approximately 300 dermatologists
in The Netherlands. Every dermatologist treats approxi-
mately 75 (minimum 50, maximum 100) psoriasis patients.
Consequently, approximately 22,500 (300 9 75) psoriasis
patients are treated by dermatologists.
Proportion of patients eligible for treatment with the new
pharmaceutical This proportion has been based tradi-
tionally on the registered indication for the new pharma-
ceutical but, beginning in the last decade, reimbursement
authorities have increasingly imposed prescription restric-
tions. For example, biologicals in RA in The Netherlands
and Germany are restricted to patients with a failure to two
disease-modifying antirheumatic drugs (DMARDs) instead
of the broader registered indication, which required only a
failure to one DMARD.
This input variable may be derived from the published
literature—ideally country-speciﬁc literature, e.g. a previ-
ous BIA for medications with similar indication, which
allows the construction of statistical distributions for the
standard sensitivity analysis. For example, the proportion of
oncology patients eligible for standard 1-line or 2-line
treatment is usually well documented for oncology indica-
tions with a high prevalence, e.g. colon carcinoma, lung
carcinoma, and breast carcinoma. However, this epidemio-
logical information might not be available when an existing
indication, e.g. 2-line treatment in oncology, is further
restricted leading to a new niche and therefore lacking
existing epidemiology data. National databases, which
contain prescription data, can sometimes provide the pro-
portion of eligible patients. However, a limitation of most
prescription databases is that they provide only utilisation
data for all drugs, but without the option of categorisation
according to different indications. Therefore, this type of
database is an appropriate data source only when the current
standard treatment for the indication of the new pharma-
ceuticalconsists ofmedication thatisnot prescribed inother
indications. For example, biologicals were prescribed ini-
tiallyonlyinRAandthereforeactualuseofbiologicalsfrom
a database would be a reliable estimate of the proportion of
eligible patients for a BIA for new pharmaceuticals in this
restricted indication. However, most current biologicals for
RA are now also prescribed in other disease areas and
therefore prescription data on biologicals from a database
wouldcurrentlynotprovideinformationoftheproportionof
eligible patients for this new pharmaceutical (of course
depending maybe on other information recorded in the
corresponding database). The standard treatment for a new
pharmaceutical may not always be another medication. For
example, a new pharmaceutical may be indicated for
patientswhoarecandidatesforacardiovascularintervention
[e.g. coronary artery bypass grafting (CABG) or percuta-
neous transluminal coronary angioplasty (PTCA)]. In this
case, the proportion of eligible patients may be derived from
national hospitalisationstatistics. However, often there is no
data available on the proportion of eligible patients, and the
use of a Delphi panel is required to elicit an estimate of the
proportion of eligible patients. For example, in the above-
mentioned BIA analysis for biologicals in psoriasis, the
panel estimated that 7% of patients treated by a dermatolo-
gist (minimum 5%, maximum 10%) are estimated to meet
the prescription criteria. This percentage leads to 1,575 (7%
of 22,500) candidates for biologicals.
Proportion of eligible patients actually treated with the
new pharmaceutical The majority of patients have clini-
cal grounds for treatment, but reasons for non-treatment
with a biological may also be patient-related, especially
considering the risk of adverse events and contra-indica-
tions. The main reason for a patient’s refusal is the fear of
adverse events or a dislike of the mode of administration. A
Dutch survey showed that only 75% of all potential RA
patients are treated with a biological, implying that nearly
25% of RA patients are not treated for various reasons.
Clinical reasons might include risk of infection, planned
pregnancy, expected low compliance, and malignancy. RA
patients themselves may dislike the subcutaneous route of
administration or the short hospital stays required for
intravenous administration of biologicals [12].
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than an actual ﬁgure, and therefore no real data is available
for this input variable. Sometimes a previous BIA for
medications with similar indication may provide relevant
information, but a BIA is often performed for a new
treatment that has no clinically equivalent existing medi-
cation. Clinical trial data may provide some information
based on inclusion and exclusion criteria and reported
adverse events, but those data may not reﬂect daily prac-
tise. Therefore, the only option seems to be to use a Delphi
panel in order elicit forecasts on the actual proportion of
patients that might be candidates for treatment with the
new pharmaceutical. Drug information on contra-indica-
tions, drug interactions and safety may be provided to the
Delphi panel on order to elicit a clinical justiﬁed estimate.
In the BIA for biologicals in psoriasis referred to above, the
panel members estimated that about 25% of all patients
meeting the prescription criteria would not actually be
treated with biologicals.
Proportion of patients included in clinical trials Clinical
trials can be categorised into phase III trials for regis-
tration and phase IV trials after market approval. This
distinction is important because of the differential impact
on the utilisation of new medications. In a phase III trial,
patients are randomised to the study drug and its com-
parator, which are provided by the study sponsor. Con-
sequently, phase III trials will reduce the potential total
national budgetary impact if those trials are going to be
performed for another new pharmaceutical with a similar
target indication. In phase IV studies, patients are using
standard treatment and their medication costs contribute
to the budgetary impact. However, phase IV studies may
have an impact on the distribution of the current treat-
ment mix, which may be especially relevant for
biologicals.
Information on ongoing clinical trials for new com-
petitive pharmaceuticals may be derived from the FDA or
the EMEA. This information (study countries and number
of sites, sample size) may be used to estimate the potential
number of patients in the country of the BIA. New
competitive pharmaceuticals, which are currently in
phase II, may also lead to clinical phase III trials. How-
ever, as phase III trials may not yet have been submitted
to registration authorities for approval (in the country of
interest), it is difﬁcult to estimate a potential number
of patients. The use of a Delphi panel for this type of
information is also not a reliable source, as clinical experts
may also not have this information, with the exception of
some clinical opinion leaders who might be involved as
investigators and may provide estimates. On the other
hand, they may have conﬁdentiality conﬂicts prohibiting
the use of such input.
Growth in utilisation
This refers to the annual growth in utilisation of the new
pharmaceutical over the time horizon of the BIA. The
actual number of eligible patients might be based on the
assumption that the annual increase of eligible patients
equals the annual growth rate of the total population.
However, changes in prescription restriction guidelines
may lead to a different growth of the actual number of
eligible patients. For example, the indication for reim-
bursement might be broadened, leading to a relative growth
rate of eligible patients higher than that of the total popu-
lation. On the other hand, there may also be a pool of
eligible patients with previous failures to current standard
treatment, which will lead to a temporary higher growth
than the annual growth of the total population. Published
information in the public domain and information spread
by patient societies contribute to this inﬂow of ‘‘old’’
patients. Changes in treatment patterns or guidelines may
also lead to differential growth of annual utilisation. For
example, continuous treatment with biologicals in RA
patients may be changed to cyclic treatment, leading to
lower annual drug use per patient.
This input variable is also a prediction (or forecast)
instead of an actual ﬁgure, and therefore no real data is
available for this input variable of the BIA. Historical data
on annual growth over the previous 5 years might be
extrapolated for an additional 3 years. This approach could
be validated with a Delphi panel or a previous BIA for
medications with similar indication, if the anticipated drug
costs for the new pharmaceutical are not very different.
Changes in prescription restriction and guidelines
Possible changes in prescription restriction and guidelines
may also lead to different drug utilisation, which requires
two estimates: (1) probability of change in guidelines, (2)
likely reduction in drug utilisation following from that
regulatory step. As discussed earlier, the pool of patients
with previous treatment failures is difﬁcult to obtain from
real data. However, recent BIA for medications that have
been reviewed for reimbursement may provide useful
information. An example might be a recent BIA report
from the Netherlands for a potential new medication for
patients with similar indications to cinacalcet (for sec-
ondary hyperparathyroidism in renal failure) [13]. The
temporary pool of patients consists of patients previously
failing on cinacalcet because of lack of response or adverse
events. This report for cinacalcet mentions that only 50%
of patients starting cinacalcet will continue treatment.
Hence, based on the patient population of 1,040 patients,
there is a pool of 520 patients that might be eligible for the
new medication. If such information is not available, a
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should be noted that not all of these patients will actually
switch to the new treatment. These ﬁgures also have to be
derived from a Delphi panel.
Distribution of existing mix of available treatment
modalities at time of launch
Relevant comparators may include other drugs, other
kinds of medical care such as surgery or watchful waiting,
or no treatment. Because of the time horizon of a BIA,
the future distribution of the available treatment modali-
ties is also required, which may also include the inclusion
of new treatment modalities at the phase III clinical trial
stage that are highly likely to be registered after launch.
Because of the time horizon of the BIA, new treatment
modalities in earlier stages of clinical development are
probably not relevant. It is often difﬁcult to explain the
distribution of existing treatment modalities from a clin-
ical point of view. The treatment decision often is rather
subjective, sometimes also depending on non-clinical
criteria, e.g. patient preferences or ﬁnancial grounds. For
example, reimbursement of inﬂiximab is based on the
regulation of expensive inpatient drugs in the Nether-
lands: 80% of the drug is reimbursed, with the other 20%
being the responsibility of the hospital. Hence, there could
be a ﬁnancial incentive to prescribe etanercept or ada-
limumab, because those biologicals are fully reimbursed.
Another non-clinical determinant of treatment selection is
that some patients participate in clinical studies (cohort
studies) and the study protocol determines the treatment
patterns.
These data may be derived from the published litera-
ture—ideally country-speciﬁc literature, e.g. a previous
BIA for medications with similar indication, which allows
the construction of statistical distributions for the standard
sensitivity analysis. National databases that contain pre-
scription data may also provide the distribution of existing
treatments. However, a limitation of most prescription
databases is that they provide only utilisation data for all
drugs, but without the option of categorisation according to
different indications as mentioned before. In addition, the
mix may also include non-medication, which is not inclu-
ded in prescription databases. As a result, the use of a
Delphi panel might also be required to elicit an estimate of
the distribution of existing treatments.
Dosing
Dosing may be based on labelling information. However,
dosing in daily practise may differ from dosing in labelling
information. For example, a Dutch study by van den Bemt
showed that the mean ratio for etanercept was 0.92,
implicating that etanercept was, on average, used slightly
less then once weekly [14].
For existing treatment, actual dosing in daily practise
may be preferred instead of labelling information, if pub-
lished data is available. Dosing for the new medication can
be based only on labelling information at time of launch.
Future distribution of available treatment modalities
This input variable is also a prediction (or forecast) instead
of an actual ﬁgure and therefore no real data is available for
this input variable. Historical data cannot be applied for
treatment modalities, which was an option for forecast on
annual growth, although previous BIA for medications
with similar indication may provide relevant information.
As a result, also in this case the use of a Delphi panel is
required to elicit an estimate of the distribution of existing
treatments or to validate estimates from another BIA.
Treatment sequencing
If the indication for the new pharmaceutical is a ﬁrst-line
treatment, patients with treatment failure may switch to a
second-line treatment that is currently also used as a ﬁrst-
line treatment. When similar drugs are used as ﬁrst-, sec-
ond- or third-line treatments, relevant data from daily
practice will be very hard to ﬁnd. As mentioned above,
databases that contain prescription data may not categorise
drugs according to indication, and also may not register the
treatment sequence. Checking whether a reimbursement
database is able to deliver that kind of data is always
advisable. Nevertheless, in most cases the use of a Delphi
panel is still required for obtaining this type of information.
Diffusion (or uptake) curves over the follow-up period in
the BIA
Diffusion (or uptake) curves reﬂect the annual proportion
of patients switching from each treatment modality of the
treatment mix to the new pharmaceutical. In the ﬁnancial
analysis, diffusion generally increases from time of launch
over the follow-up period. This input variable is also a
prediction (or forecast) instead of an actual ﬁgure and
therefore no real data should be available. Ideally, the
uptake curve for each separate treatment option should be
estimated instead of a general uptake from the total treat-
ment mix. One reason for this might be that deviations in
uptake for expensive, frequently applied, treatment options
will have a much higher impact than a similar uptake from
cheap but rare treatment options. Historical data on diffu-
sion curves from recent BIA analyses for a medication with
a similar indication may be considered. However, if the
new medication differs substantially in clinical properties
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cable, but instead may be used as starting point for a Delphi
panel. In all cases, the anticipated uptake for the new
medication in relation to previous medications is, of
course, not available in existing BIAs. In particular, if the
uptake relates to an expensive treatment requiring hospi-
talisation, the impact on the total budget might be sub-
stantial, making this a highly sensitive input factor.
Substitution effects
The switch from an existing treatment modality to the new
pharmaceutical may also lead to other substitution effects,
for example a change in dosage and/or type of co-medi-
cation, or a change in other resource utilisation (consulta-
tions, hospitalisation). For example, a switch from
adalimumab or etanercept to inﬂiximab in RA treatment
would lead to additional hospitalisation costs because of
the need for inpatient intravenous administration of inf-
liximab. Substitution effects might have an impact on the
drug budget, but more usually on the total health budget.
One economic study showed that the total annual drug
costs per patient do not differ substantially between eta-
nercept and inﬂiximab, with costs of € 15,012 and €
14,921, respectively [15]. However, other medical costs
(i.e. excluding the costs of the two drugs themselves) are
substantially higher for inﬂiximab, which is due to the
additional costs associated with day-care and use of
methotrexate (MTX; € 6,010).
These effects might be derived from differences in the
treatment patterns associated with the previous and the new
medication. For example, a switch from adalimumab or
etanercept to inﬂiximab in rheumatoid arthritis therapy
would lead to additional hospitalisation costs caused by the
need for inpatient intravenous administration of inﬂiximab.
A difference in clinical properties of the new medication
(safety, warnings, contra-indications and route of admin-
istration) compared with existing treatment options might
be followed by different resource utilisation, which could
be evaluated by real practice data or alternatively as a
starting point for a Delphi panel.
Off-label
Off-label use means that the drug is used outside its reg-
istered indication, usually in subpopulation(s) where ofﬁ-
cially registered drugs are not efﬁcacious or lead to
intolerable side effects. Off-label use can have substantial
budgetary implications. The risk of off-label use is espe-
cially high when registration trials are running for the same
drug in other indications. Based on preliminary ﬁndings,
physicians may already start to prescribe the drug before its
ofﬁcial registration, especially when the new indication is
related to the currently registered indication. For example,
biologicals were initially approved for RA, but early clin-
ical trial data already showed clinical evidence for bio-
logicals in related rheumatoid disorders like ankylosing
spondylitis. Therefore, health authorities often proactively
incorporate off-label use in BIAs. It is important to note
that restricted use and the risk of off-label use are not
mutually exclusive. For example, a new innovative drug
may be limited within the registered indication, but the risk
of off-label use still exists. An example is the prescription
restriction of biologicals to a severe subpopulation within
the RA indication (failure to two DMARDs instead of one
DMARD). On the other hand, there was also a risk of off-
label use in related diseases like ankylosing spondylitis.
The ﬁnancial analysis of off-label use usually cannot rely
solely on an existing cost-effectiveness study for the new
pharmaceutical, which focusses only on the registered
indication. Therefore, separate submodels for off-label
indications need to be developed. The use of a drug that is
reimbursed only with restricted use, within its registered
indication, but outside the restricted indication, is a special
form of off-label use. Off-label data is also a prediction (or
forecast) instead of an actual ﬁgure and therefore no real
data is available. These data may be derived from a pre-
vious BIA for medications with a similar indication, with a
Delphi panel as the last remaining option in the absence of
any alternative.
Discussion
The objective of this paper was to address the importance
of dealing systematically and comprehensively with
uncertainty in a BIA in more detail. The handling of
uncertainty in health economics was used as a point of
reference for addressing the uncertainty in a BIA.
The overview showed that standard methods of sensi-
tivity analysis, which are used for standard data set in a
cost-effectiveness model (clinical probabilities, treatment
patterns, resource utilisation and prices/tariffs), cannot
always be used as input data for the BIA model beyond the
cost-effectiveness data set for various reasons:
The data set in a cost-effectiveness model comes mainly
from actual data sources: clinical trials, literature (e.g. meta-
analysis), databases, medical records, and/or ofﬁcial tariffs,
which allows the construction of a statistical distribution of
an input variable. This distribution can be used for 1-way
sensitivity analysis (using a conﬁdence interval in addition)
or a PSA. In some cases, a Delphi panel will be required to
obtain missing data, which usually relates to health care
utilisation. A statistical distribution may also be constructed
for data from a Delphi panel, although this uncertainty
captures only the variance in the estimates, not the
Budget impact analysis 239
123uncertainty of a Delphi panel compared with actual data. It
was shown that the availability of appropriate data sources
for BIA data will often be limited for the part of the BIA
modelthatdoesnotcapturethehealtheconomiccomponent.
Dataonprevalenceandincidencemayoftenbederivedfrom
the literature, but most other BIA data can be derived only
from a Delphi panel. Whereas in a cost-effectiveness model,
only limited data may come from a Delphi panel, a BIA
model often relies on aDelphi panel for the majority of data.
Although a statistical distribution may also be constructed
forsuchBIA, the impactofthe uncertainty ofaDelphi panel
might be much larger compared with actual data.
In addition, the data set in a cost-effectiveness model
relates only to existing data, whereas the data in a BIA
model also includes forecasts, e.g. annual growth, uptakes
curves, substitution effects, changes in prescription
restrictions and guidelines, future distribution of the avail-
able treatment modalities, and off-label use. In some cases,
mathematical methods of extrapolation may be used, for
example using data on historical trends, which could help in
the estimation of distributional properties. Nevertheless,
this variance captures only the statistical uncertainty, but
not the uncertainty in the assumptions for the forecast. In
the majority of cases the use of a Delphi panel seems to be
the only option for obtaining this type of information.
Summarising, one conclusion could be that given the
estimation of statistical distributions for all input variables
of a BIA analysis, it is possible to capture the uncertainty in
the variance, but the impact of the level in uncertainty
could be much larger than in a health economic data set of
the same BIA model. As a consequence it might be ques-
tioned if a sensitivity analysis on the BIA data set sufﬁ-
ciently captures uncertainty in the outcome of the model.
The cost-effectiveness model calculates costs at the
patient level, whereas the BIA calculates costs at a popu-
lation level. Therefore, separate sensitivity analyses may be
performed on the cost-effectiveness data set and the results
may be reported for costs at patient level. This analysis
does not depend on the additional BIA dataset, and there-
fore standard sensitivity analyses can be applied. A PSA
can also be performed, exploring the probability of whether
the cost difference at patient level exceeds a predeﬁned
threshold. As decision-makers for a BIA analysis might
differ from the target audience for a CEA, the relevance of
a PSA might be questioned. Cost-effectiveness in most
jurisdictions might be a criterion at a more central level,
whereas most decision-makers are at regional level.
Decision-makers with budget responsibility often are
not familiar with the speciﬁc terminology from health
economics, for example PSA and cost-effectiveness
acceptability curves. The use of PSA for calculating budget-
acceptability curves might provide relevant information
regarding outcome uncertainty, but may not be relevant for
the target audience. In addition, their set of decision criteria
might be different and their handling of uncertainty may
rely on methods other than the sensitivity analyses used in
health economics. Therefore, different scenario analyses
could be a more useful approach for this type of decision-
maker. While a sensitivity analysis is based on the modiﬁ-
cation of clinical and economic estimates of input variables
over a plausible range of values, a scenario analysis is based
on the modiﬁcation of the underlying therapeutic strategies
of the model: e.g. society perspective, life-time horizon.
The use of standard sensitivity analyses for the BIA
dataset might also be limited because of the lack of
appropriate distributions as data sources or the need for
forecasting. Again, scenario analyses might be more
appropriate to capture the uncertainty in the BIA dataset of
the overall BIA model. But, having said that, sensitivity
analysis for the BIA set may not be useful; one-way sen-
sitivity analyses may still be informative, i.e. testing for
sensitivity to input variables, e.g. by using exploring
extreme values, ±25% or a 1-way sensitivity analysis based
on minimum and maximum values of the distribution.
Another option to estimate the level of uncertainty
would be to use point-sensitivity analysis. The advantage
of this approach would be that this type of sensitivity
analysis provides information on the sensitivity of the
model to the input variable regardless of the range. This
could be especially appropriate for the speciﬁc BIA dataset,
as particularly the range is uncertain. To take account of
the ﬁxed input value, sensitivity is best calculated by
comparing the percentage change in input value to the
percentage change in outcome value [16]. Therefore, this
equation can provide a measure of the responsiveness of
one item in relation to the other. In the end, point-sensi-
tivity shows how critical a variable really is for the model
and allows a comparison between all variables that is not
confounded by the range of each variable.
Summarising, because BIA is used for reimbursement
issuesbyauthoritiesorthird-partypayers,itisvitalthatthese
analyses are performed according to generally accepted and
standardisedmethods.Thisincreasesthetransparencyofany
ﬁnancialanalysis,allowingforamorerationalinterpretation
of the BIA results and a better comparison of different
analyses for various new pharmaceuticals.
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